Lung cancer trial matches drugs to tumor DNA
NCT ID NCT02314481
First seen May 07, 2026 · Last updated Jun 07, 2026 · Updated 6 times
Summary
This study tested whether giving drugs based on the genetic makeup of a person's lung cancer could help control the disease. About 50 adults with advanced non-small cell lung cancer received either immunotherapy (atezolizumab) alone or with chemotherapy, or targeted drugs like vemurafenib, trastuzumab emtansine, or alectinib depending on their tumor's mutations. The goal was to see how long the cancer stayed under control and to learn which genetic markers predict response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Univeristy College London Hospital
London, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.